Global Vector Based RNAi Market
Global Vector Based RNAi Market

Vector Based RNAi Comprehensive Study by Type (MicroRNA (miRNA), Small interfering RNA (siRNA)), Application (Neurological Disorders, Oncology, Ocular Disorders, Hepatitis B and C, Autoimmune Hepatitis, Therapeutics, Respiratory Disorders, Other), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Vector Based RNAi Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 221 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Vector-based RNA interference is a therapeutic and illness management technique that reduces gene translation or expression suppression while neutralizing the targeted mRNA molecules. In cancer therapy, vector-based RNAi plays an important role. Its usage in association with genetically designed viral vectors like lentivirus allows for high shRNA delivery efficiency or incorporation into genomic DNA for persistent shRNA expression.This growth is primarily driven by Demand to Improvement in Synthetic Delivery Carriers and Rise of Several Applications in Molecular Diagnostic and Need to Regulate Gene Inhibition with Inducible RNAi Expression.

Globally, a noticeable market trend is evident Advancement in Vector-Based RNAi Technologies to Produce Small Hairpin RNA (shRNA) Driven by the U6 or H1 Promoter. Major Players, such as Thermo Fisher Scientific (United States), Merck KGaA (Germany), Phio Pharmaceuticals Corp. (United States), Quark Pharmaceuticals Inc. (Israel), Silence Therapeutics PLC (United Kingdom), Qiagen N.V. (Germany), GenScript (United States), Ionis Pharmaceuticals Inc. (United States), Dicerna Pharmaceuticals (United States) and Arrowhead Pharmaceuticals (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Regulatory Insights:
“According to NCBI, US National Library of Medicine, National Institute of Health, viral-mediated delivery delivers siRNA using recombinant viral vectors such as retrovirus, adeno-associated virus (AAVs), adenovirus, and lentivirus. It's suitable for primary and non-dividing cells, as well as in vivo studies for long-term expression. However, issues arise because of the potential for mutagenic and immunogenic consequences, as well as the requirement to produce and titrate viral particles. The production of an shRNA, which causes permanent reduction of gene expression, has been created as a vector-based approach for gene silencing.”

Market Drivers
  • Demand to Improvement in Synthetic Delivery Carriers and Rise of Several Applications in Molecular Diagnostic
  • Need to Regulate Gene Inhibition with Inducible RNAi Expression

Market Trend
  • Advancement in Vector-Based RNAi Technologies to Produce Small Hairpin RNA (shRNA) Driven by the U6 or H1 Promoter

Restraints
  • High Cost Associated with the Vector-Based RNA Interference

Opportunities
Advantages Such as Including Ease of Implementation and Compatibility for a Wide Range of Cell Lines
Challenges
Problem Faced by the Companies for the Approval of USFDA of a Product Launch

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Vector Based RNAi Study Sheds Light on
— The Vector Based RNAi Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Vector Based RNAi industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Vector Based RNAi industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Vector Based RNAi Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: to 2026

2. Who are the key players profiled in the Vector Based RNAi Market?
Companies that are profiled in Global Vector Based RNAi Market are Thermo Fisher Scientific (United States), Merck KGaA (Germany), Phio Pharmaceuticals Corp. (United States), Quark Pharmaceuticals Inc. (Israel), Silence Therapeutics PLC (United Kingdom), Qiagen N.V. (Germany), GenScript (United States), Ionis Pharmaceuticals Inc. (United States), Dicerna Pharmaceuticals (United States) and Arrowhead Pharmaceuticals (United States) etc.

3. What is Vector Based RNAi Market?
Vector-based RNA interference is a therapeutic and illness management technique that reduces gene translation or expression suppression while neutralizing the targeted mRNA molecules. In cancer therapy, vector-based RNAi plays an important role. Its usage in association with genetically designed viral vectors like lentivirus allows for high shRNA delivery efficiency or incorporation into genomic DNA for persistent shRNA expression.
Report Objectives / Segmentation Covered
By Type
  • microRNA (miRNA)
  • small interfering RNA (siRNA)
By Application
  • Neurological Disorders
  • Oncology
  • Ocular Disorders
  • Hepatitis B and C
  • Autoimmune Hepatitis
  • Therapeutics
  • Respiratory Disorders
  • Other
By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Demand to Improvement in Synthetic Delivery Carriers and Rise of Several Applications in Molecular Diagnostic
      • 3.2.2. Need to Regulate Gene Inhibition with Inducible RNAi Expression
    • 3.3. Market Challenges
      • 3.3.1. Problem Faced by the Companies for the Approval of USFDA of a Product Launch
    • 3.4. Market Trends
      • 3.4.1. Advancement in Vector-Based RNAi Technologies to Produce Small Hairpin RNA (shRNA) Driven by the U6 or H1 Promoter
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vector Based RNAi, by Type, Application, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vector Based RNAi (Value)
      • 5.2.1. Global Vector Based RNAi by: Type (Value)
        • 5.2.1.1. MicroRNA (miRNA)
        • 5.2.1.2. Small interfering RNA (siRNA)
      • 5.2.2. Global Vector Based RNAi by: Application (Value)
        • 5.2.2.1. Neurological Disorders
        • 5.2.2.2. Oncology
        • 5.2.2.3. Ocular Disorders
        • 5.2.2.4. Hepatitis B and C
        • 5.2.2.5. Autoimmune Hepatitis
        • 5.2.2.6. Therapeutics
        • 5.2.2.7. Respiratory Disorders
        • 5.2.2.8. Other
      • 5.2.3. Global Vector Based RNAi by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Vector Based RNAi Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Vector Based RNAi (Volume)
      • 5.3.1. Global Vector Based RNAi by: Type (Volume)
        • 5.3.1.1. MicroRNA (miRNA)
        • 5.3.1.2. Small interfering RNA (siRNA)
      • 5.3.2. Global Vector Based RNAi by: Application (Volume)
        • 5.3.2.1. Neurological Disorders
        • 5.3.2.2. Oncology
        • 5.3.2.3. Ocular Disorders
        • 5.3.2.4. Hepatitis B and C
        • 5.3.2.5. Autoimmune Hepatitis
        • 5.3.2.6. Therapeutics
        • 5.3.2.7. Respiratory Disorders
        • 5.3.2.8. Other
      • 5.3.3. Global Vector Based RNAi by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Specialty Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global Vector Based RNAi Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Vector Based RNAi (Price)
      • 5.4.1. Global Vector Based RNAi by: Type (Price)
  • 6. Vector Based RNAi: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Phio Pharmaceuticals Corp. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Quark Pharmaceuticals Inc. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Silence Therapeutics PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Qiagen N.V. (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GenScript (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ionis Pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dicerna Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arrowhead Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Vector Based RNAi Sale, by Type, Application, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vector Based RNAi (Value)
      • 7.2.1. Global Vector Based RNAi by: Type (Value)
        • 7.2.1.1. MicroRNA (miRNA)
        • 7.2.1.2. Small interfering RNA (siRNA)
      • 7.2.2. Global Vector Based RNAi by: Application (Value)
        • 7.2.2.1. Neurological Disorders
        • 7.2.2.2. Oncology
        • 7.2.2.3. Ocular Disorders
        • 7.2.2.4. Hepatitis B and C
        • 7.2.2.5. Autoimmune Hepatitis
        • 7.2.2.6. Therapeutics
        • 7.2.2.7. Respiratory Disorders
        • 7.2.2.8. Other
      • 7.2.3. Global Vector Based RNAi by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Vector Based RNAi Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Vector Based RNAi (Volume)
      • 7.3.1. Global Vector Based RNAi by: Type (Volume)
        • 7.3.1.1. MicroRNA (miRNA)
        • 7.3.1.2. Small interfering RNA (siRNA)
      • 7.3.2. Global Vector Based RNAi by: Application (Volume)
        • 7.3.2.1. Neurological Disorders
        • 7.3.2.2. Oncology
        • 7.3.2.3. Ocular Disorders
        • 7.3.2.4. Hepatitis B and C
        • 7.3.2.5. Autoimmune Hepatitis
        • 7.3.2.6. Therapeutics
        • 7.3.2.7. Respiratory Disorders
        • 7.3.2.8. Other
      • 7.3.3. Global Vector Based RNAi by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Specialty Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global Vector Based RNAi Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Vector Based RNAi (Price)
      • 7.4.1. Global Vector Based RNAi by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vector Based RNAi: by Type(USD Million)
  • Table 2. Vector Based RNAi MicroRNA (miRNA) , by Region USD Million (2015-2020)
  • Table 3. Vector Based RNAi Small interfering RNA (siRNA) , by Region USD Million (2015-2020)
  • Table 4. Vector Based RNAi: by Application(USD Million)
  • Table 5. Vector Based RNAi Neurological Disorders , by Region USD Million (2015-2020)
  • Table 6. Vector Based RNAi Oncology , by Region USD Million (2015-2020)
  • Table 7. Vector Based RNAi Ocular Disorders , by Region USD Million (2015-2020)
  • Table 8. Vector Based RNAi Hepatitis B and C , by Region USD Million (2015-2020)
  • Table 9. Vector Based RNAi Autoimmune Hepatitis , by Region USD Million (2015-2020)
  • Table 10. Vector Based RNAi Therapeutics , by Region USD Million (2015-2020)
  • Table 11. Vector Based RNAi Respiratory Disorders , by Region USD Million (2015-2020)
  • Table 12. Vector Based RNAi Other , by Region USD Million (2015-2020)
  • Table 13. Vector Based RNAi: by End User(USD Million)
  • Table 14. Vector Based RNAi Hospitals , by Region USD Million (2015-2020)
  • Table 15. Vector Based RNAi Specialty Clinics , by Region USD Million (2015-2020)
  • Table 16. Vector Based RNAi Others , by Region USD Million (2015-2020)
  • Table 17. South America Vector Based RNAi, by Country USD Million (2015-2020)
  • Table 18. South America Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 19. South America Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 20. South America Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 21. Brazil Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 22. Brazil Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 23. Brazil Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 24. Argentina Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 25. Argentina Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 26. Argentina Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 27. Rest of South America Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 30. Asia Pacific Vector Based RNAi, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 34. China Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 35. China Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 36. China Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 37. Japan Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 38. Japan Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 39. Japan Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 40. India Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 41. India Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 42. India Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 43. South Korea Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 44. South Korea Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 45. South Korea Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 46. Taiwan Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 47. Taiwan Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 48. Taiwan Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 49. Australia Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 50. Australia Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 51. Australia Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 55. Europe Vector Based RNAi, by Country USD Million (2015-2020)
  • Table 56. Europe Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 57. Europe Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 58. Europe Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 59. Germany Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 60. Germany Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 61. Germany Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 62. France Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 63. France Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 64. France Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 65. Italy Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 66. Italy Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 67. Italy Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 68. United Kingdom Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 71. Netherlands Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 72. Netherlands Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 73. Netherlands Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 74. Rest of Europe Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 77. MEA Vector Based RNAi, by Country USD Million (2015-2020)
  • Table 78. MEA Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 79. MEA Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 80. MEA Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 81. Middle East Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 82. Middle East Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 83. Middle East Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 84. Africa Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 85. Africa Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 86. Africa Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 87. North America Vector Based RNAi, by Country USD Million (2015-2020)
  • Table 88. North America Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 89. North America Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 90. North America Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 91. United States Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 92. United States Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 93. United States Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 94. Canada Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 95. Canada Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 96. Canada Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 97. Mexico Vector Based RNAi, by Type USD Million (2015-2020)
  • Table 98. Mexico Vector Based RNAi, by Application USD Million (2015-2020)
  • Table 99. Mexico Vector Based RNAi, by End User USD Million (2015-2020)
  • Table 100. Vector Based RNAi Sales: by Type(K Units)
  • Table 101. Vector Based RNAi Sales MicroRNA (miRNA) , by Region K Units (2015-2020)
  • Table 102. Vector Based RNAi Sales Small interfering RNA (siRNA) , by Region K Units (2015-2020)
  • Table 103. Vector Based RNAi Sales: by Application(K Units)
  • Table 104. Vector Based RNAi Sales Neurological Disorders , by Region K Units (2015-2020)
  • Table 105. Vector Based RNAi Sales Oncology , by Region K Units (2015-2020)
  • Table 106. Vector Based RNAi Sales Ocular Disorders , by Region K Units (2015-2020)
  • Table 107. Vector Based RNAi Sales Hepatitis B and C , by Region K Units (2015-2020)
  • Table 108. Vector Based RNAi Sales Autoimmune Hepatitis , by Region K Units (2015-2020)
  • Table 109. Vector Based RNAi Sales Therapeutics , by Region K Units (2015-2020)
  • Table 110. Vector Based RNAi Sales Respiratory Disorders , by Region K Units (2015-2020)
  • Table 111. Vector Based RNAi Sales Other , by Region K Units (2015-2020)
  • Table 112. Vector Based RNAi Sales: by End User(K Units)
  • Table 113. Vector Based RNAi Sales Hospitals , by Region K Units (2015-2020)
  • Table 114. Vector Based RNAi Sales Specialty Clinics , by Region K Units (2015-2020)
  • Table 115. Vector Based RNAi Sales Others , by Region K Units (2015-2020)
  • Table 116. South America Vector Based RNAi Sales, by Country K Units (2015-2020)
  • Table 117. South America Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 118. South America Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 119. South America Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 120. Brazil Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 121. Brazil Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 122. Brazil Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 123. Argentina Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 124. Argentina Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 125. Argentina Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 126. Rest of South America Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 127. Rest of South America Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 128. Rest of South America Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 129. Asia Pacific Vector Based RNAi Sales, by Country K Units (2015-2020)
  • Table 130. Asia Pacific Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 131. Asia Pacific Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 132. Asia Pacific Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 133. China Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 134. China Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 135. China Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 136. Japan Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 137. Japan Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 138. Japan Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 139. India Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 140. India Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 141. India Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 142. South Korea Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 143. South Korea Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 144. South Korea Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 145. Taiwan Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 146. Taiwan Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 147. Taiwan Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 148. Australia Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 149. Australia Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 150. Australia Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 151. Rest of Asia-Pacific Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 152. Rest of Asia-Pacific Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 153. Rest of Asia-Pacific Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 154. Europe Vector Based RNAi Sales, by Country K Units (2015-2020)
  • Table 155. Europe Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 156. Europe Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 157. Europe Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 158. Germany Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 159. Germany Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 160. Germany Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 161. France Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 162. France Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 163. France Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 164. Italy Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 165. Italy Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 166. Italy Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 167. United Kingdom Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 168. United Kingdom Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 169. United Kingdom Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 170. Netherlands Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 171. Netherlands Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 172. Netherlands Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 173. Rest of Europe Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 174. Rest of Europe Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 175. Rest of Europe Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 176. MEA Vector Based RNAi Sales, by Country K Units (2015-2020)
  • Table 177. MEA Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 178. MEA Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 179. MEA Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 180. Middle East Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 181. Middle East Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 182. Middle East Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 183. Africa Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 184. Africa Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 185. Africa Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 186. North America Vector Based RNAi Sales, by Country K Units (2015-2020)
  • Table 187. North America Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 188. North America Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 189. North America Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 190. United States Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 191. United States Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 192. United States Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 193. Canada Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 194. Canada Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 195. Canada Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 196. Mexico Vector Based RNAi Sales, by Type K Units (2015-2020)
  • Table 197. Mexico Vector Based RNAi Sales, by Application K Units (2015-2020)
  • Table 198. Mexico Vector Based RNAi Sales, by End User K Units (2015-2020)
  • Table 199. Vector Based RNAi: by Type(USD/Units)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Vector Based RNAi: by Type(USD Million)
  • Table 211. Vector Based RNAi MicroRNA (miRNA) , by Region USD Million (2021-2026)
  • Table 212. Vector Based RNAi Small interfering RNA (siRNA) , by Region USD Million (2021-2026)
  • Table 213. Vector Based RNAi: by Application(USD Million)
  • Table 214. Vector Based RNAi Neurological Disorders , by Region USD Million (2021-2026)
  • Table 215. Vector Based RNAi Oncology , by Region USD Million (2021-2026)
  • Table 216. Vector Based RNAi Ocular Disorders , by Region USD Million (2021-2026)
  • Table 217. Vector Based RNAi Hepatitis B and C , by Region USD Million (2021-2026)
  • Table 218. Vector Based RNAi Autoimmune Hepatitis , by Region USD Million (2021-2026)
  • Table 219. Vector Based RNAi Therapeutics , by Region USD Million (2021-2026)
  • Table 220. Vector Based RNAi Respiratory Disorders , by Region USD Million (2021-2026)
  • Table 221. Vector Based RNAi Other , by Region USD Million (2021-2026)
  • Table 222. Vector Based RNAi: by End User(USD Million)
  • Table 223. Vector Based RNAi Hospitals , by Region USD Million (2021-2026)
  • Table 224. Vector Based RNAi Specialty Clinics , by Region USD Million (2021-2026)
  • Table 225. Vector Based RNAi Others , by Region USD Million (2021-2026)
  • Table 226. South America Vector Based RNAi, by Country USD Million (2021-2026)
  • Table 227. South America Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 228. South America Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 229. South America Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 230. Brazil Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 231. Brazil Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 232. Brazil Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 233. Argentina Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 234. Argentina Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 235. Argentina Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 236. Rest of South America Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 237. Rest of South America Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 238. Rest of South America Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 239. Asia Pacific Vector Based RNAi, by Country USD Million (2021-2026)
  • Table 240. Asia Pacific Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 241. Asia Pacific Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 242. Asia Pacific Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 243. China Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 244. China Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 245. China Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 246. Japan Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 247. Japan Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 248. Japan Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 249. India Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 250. India Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 251. India Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 252. South Korea Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 253. South Korea Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 254. South Korea Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 255. Taiwan Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 256. Taiwan Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 257. Taiwan Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 258. Australia Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 259. Australia Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 260. Australia Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 261. Rest of Asia-Pacific Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 262. Rest of Asia-Pacific Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 263. Rest of Asia-Pacific Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 264. Europe Vector Based RNAi, by Country USD Million (2021-2026)
  • Table 265. Europe Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 266. Europe Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 267. Europe Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 268. Germany Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 269. Germany Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 270. Germany Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 271. France Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 272. France Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 273. France Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 274. Italy Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 275. Italy Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 276. Italy Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 277. United Kingdom Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 278. United Kingdom Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 279. United Kingdom Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 280. Netherlands Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 281. Netherlands Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 282. Netherlands Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 283. Rest of Europe Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 284. Rest of Europe Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 285. Rest of Europe Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 286. MEA Vector Based RNAi, by Country USD Million (2021-2026)
  • Table 287. MEA Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 288. MEA Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 289. MEA Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 290. Middle East Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 291. Middle East Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 292. Middle East Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 293. Africa Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 294. Africa Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 295. Africa Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 296. North America Vector Based RNAi, by Country USD Million (2021-2026)
  • Table 297. North America Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 298. North America Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 299. North America Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 300. United States Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 301. United States Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 302. United States Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 303. Canada Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 304. Canada Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 305. Canada Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 306. Mexico Vector Based RNAi, by Type USD Million (2021-2026)
  • Table 307. Mexico Vector Based RNAi, by Application USD Million (2021-2026)
  • Table 308. Mexico Vector Based RNAi, by End User USD Million (2021-2026)
  • Table 309. Vector Based RNAi Sales: by Type(K Units)
  • Table 310. Vector Based RNAi Sales MicroRNA (miRNA) , by Region K Units (2021-2026)
  • Table 311. Vector Based RNAi Sales Small interfering RNA (siRNA) , by Region K Units (2021-2026)
  • Table 312. Vector Based RNAi Sales: by Application(K Units)
  • Table 313. Vector Based RNAi Sales Neurological Disorders , by Region K Units (2021-2026)
  • Table 314. Vector Based RNAi Sales Oncology , by Region K Units (2021-2026)
  • Table 315. Vector Based RNAi Sales Ocular Disorders , by Region K Units (2021-2026)
  • Table 316. Vector Based RNAi Sales Hepatitis B and C , by Region K Units (2021-2026)
  • Table 317. Vector Based RNAi Sales Autoimmune Hepatitis , by Region K Units (2021-2026)
  • Table 318. Vector Based RNAi Sales Therapeutics , by Region K Units (2021-2026)
  • Table 319. Vector Based RNAi Sales Respiratory Disorders , by Region K Units (2021-2026)
  • Table 320. Vector Based RNAi Sales Other , by Region K Units (2021-2026)
  • Table 321. Vector Based RNAi Sales: by End User(K Units)
  • Table 322. Vector Based RNAi Sales Hospitals , by Region K Units (2021-2026)
  • Table 323. Vector Based RNAi Sales Specialty Clinics , by Region K Units (2021-2026)
  • Table 324. Vector Based RNAi Sales Others , by Region K Units (2021-2026)
  • Table 325. South America Vector Based RNAi Sales, by Country K Units (2021-2026)
  • Table 326. South America Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 327. South America Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 328. South America Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 329. Brazil Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 330. Brazil Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 331. Brazil Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 332. Argentina Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 333. Argentina Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 334. Argentina Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 335. Rest of South America Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 336. Rest of South America Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 337. Rest of South America Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 338. Asia Pacific Vector Based RNAi Sales, by Country K Units (2021-2026)
  • Table 339. Asia Pacific Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 340. Asia Pacific Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 341. Asia Pacific Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 342. China Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 343. China Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 344. China Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 345. Japan Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 346. Japan Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 347. Japan Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 348. India Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 349. India Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 350. India Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 351. South Korea Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 352. South Korea Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 353. South Korea Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 354. Taiwan Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 355. Taiwan Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 356. Taiwan Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 357. Australia Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 358. Australia Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 359. Australia Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 360. Rest of Asia-Pacific Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 361. Rest of Asia-Pacific Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 362. Rest of Asia-Pacific Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 363. Europe Vector Based RNAi Sales, by Country K Units (2021-2026)
  • Table 364. Europe Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 365. Europe Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 366. Europe Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 367. Germany Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 368. Germany Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 369. Germany Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 370. France Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 371. France Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 372. France Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 373. Italy Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 374. Italy Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 375. Italy Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 376. United Kingdom Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 377. United Kingdom Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 378. United Kingdom Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 379. Netherlands Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 380. Netherlands Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 381. Netherlands Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 382. Rest of Europe Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 383. Rest of Europe Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 384. Rest of Europe Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 385. MEA Vector Based RNAi Sales, by Country K Units (2021-2026)
  • Table 386. MEA Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 387. MEA Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 388. MEA Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 389. Middle East Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 390. Middle East Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 391. Middle East Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 392. Africa Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 393. Africa Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 394. Africa Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 395. North America Vector Based RNAi Sales, by Country K Units (2021-2026)
  • Table 396. North America Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 397. North America Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 398. North America Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 399. United States Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 400. United States Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 401. United States Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 402. Canada Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 403. Canada Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 404. Canada Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 405. Mexico Vector Based RNAi Sales, by Type K Units (2021-2026)
  • Table 406. Mexico Vector Based RNAi Sales, by Application K Units (2021-2026)
  • Table 407. Mexico Vector Based RNAi Sales, by End User K Units (2021-2026)
  • Table 408. Vector Based RNAi: by Type(USD/Units)
  • Table 409. Research Programs/Design for This Report
  • Table 410. Key Data Information from Secondary Sources
  • Table 411. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vector Based RNAi: by Type USD Million (2015-2020)
  • Figure 5. Global Vector Based RNAi: by Application USD Million (2015-2020)
  • Figure 6. Global Vector Based RNAi: by End User USD Million (2015-2020)
  • Figure 7. South America Vector Based RNAi Share (%), by Country
  • Figure 8. Asia Pacific Vector Based RNAi Share (%), by Country
  • Figure 9. Europe Vector Based RNAi Share (%), by Country
  • Figure 10. MEA Vector Based RNAi Share (%), by Country
  • Figure 11. North America Vector Based RNAi Share (%), by Country
  • Figure 12. Global Vector Based RNAi: by Type K Units (2015-2020)
  • Figure 13. Global Vector Based RNAi: by Application K Units (2015-2020)
  • Figure 14. Global Vector Based RNAi: by End User K Units (2015-2020)
  • Figure 15. South America Vector Based RNAi Share (%), by Country
  • Figure 16. Asia Pacific Vector Based RNAi Share (%), by Country
  • Figure 17. Europe Vector Based RNAi Share (%), by Country
  • Figure 18. MEA Vector Based RNAi Share (%), by Country
  • Figure 19. North America Vector Based RNAi Share (%), by Country
  • Figure 20. Global Vector Based RNAi: by Type USD/Units (2015-2020)
  • Figure 21. Global Vector Based RNAi share by Players 2020 (%)
  • Figure 22. Global Vector Based RNAi share by Players (Top 3) 2020(%)
  • Figure 23. Global Vector Based RNAi share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 26. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 27. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 29. Phio Pharmaceuticals Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Phio Pharmaceuticals Corp. (United States) Revenue: by Geography 2020
  • Figure 31. Quark Pharmaceuticals Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Quark Pharmaceuticals Inc. (Israel) Revenue: by Geography 2020
  • Figure 33. Silence Therapeutics PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Silence Therapeutics PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Qiagen N.V. (Germany) Revenue: by Geography 2020
  • Figure 37. GenScript (United States) Revenue, Net Income and Gross profit
  • Figure 38. GenScript (United States) Revenue: by Geography 2020
  • Figure 39. Ionis Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Ionis Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Dicerna Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 42. Dicerna Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 43. Arrowhead Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 44. Arrowhead Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 45. Global Vector Based RNAi: by Type USD Million (2021-2026)
  • Figure 46. Global Vector Based RNAi: by Application USD Million (2021-2026)
  • Figure 47. Global Vector Based RNAi: by End User USD Million (2021-2026)
  • Figure 48. South America Vector Based RNAi Share (%), by Country
  • Figure 49. Asia Pacific Vector Based RNAi Share (%), by Country
  • Figure 50. Europe Vector Based RNAi Share (%), by Country
  • Figure 51. MEA Vector Based RNAi Share (%), by Country
  • Figure 52. North America Vector Based RNAi Share (%), by Country
  • Figure 53. Global Vector Based RNAi: by Type K Units (2021-2026)
  • Figure 54. Global Vector Based RNAi: by Application K Units (2021-2026)
  • Figure 55. Global Vector Based RNAi: by End User K Units (2021-2026)
  • Figure 56. South America Vector Based RNAi Share (%), by Country
  • Figure 57. Asia Pacific Vector Based RNAi Share (%), by Country
  • Figure 58. Europe Vector Based RNAi Share (%), by Country
  • Figure 59. MEA Vector Based RNAi Share (%), by Country
  • Figure 60. North America Vector Based RNAi Share (%), by Country
  • Figure 61. Global Vector Based RNAi: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Merck KGaA (Germany)
  • Phio Pharmaceuticals Corp. (United States)
  • Quark Pharmaceuticals Inc. (Israel)
  • Silence Therapeutics PLC (United Kingdom)
  • Qiagen N.V. (Germany)
  • GenScript (United States)
  • Ionis Pharmaceuticals Inc. (United States)
  • Dicerna Pharmaceuticals (United States)
  • Arrowhead Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Arcturus Therapeutics (United States) , Alnylam Pharmaceuticals (United States) , Benitec Biopharma (Australia)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation